Posts by Alex Rosenberg

  • Why it might be time to short this highflying stock

    Alex Rosenberg at Talking Numbers1 mth ago

    Who says the house always wins?

    It’s been a  bad week for casino stocks, with the highflying sector taking a hit on news on disappointing gaming revenue out of Macau. May monthly gaming revenue came in at $4 billion, which is a rise of 9.3 percent from the year prior. That might sound awesome, but investors were hoping for more – and sold casino stocks like Las Vegas Sands and Wynn as a result.

    (Read: Vegas Sands updates investors at annual meeting)

    Of course, investors don’t have much to complain about. Over the past five years, growth from Macau has triggered rallies of about 450 percent in Wynn and 670 percent in Las Vegas Sands.

    But that very rally might be investors’ single best reason to stay away from these stocks at this point.

    “When you do the math, ultimately, you have to buy investments at a price,” pointed out Kevin Caron, portfolio manager and market strategist at Washington Crossing Advisors. “And when you look at valuation, we’re close to 12 or 13 times cash flow, EBITDA [earnings before taxes, depreciation, and amortization], so to me it’s not really a tremendous value here. Maybe you could buy it at better prices.”

    Read More

  • Immune Pharmaceuticals Announces First Quarter 2014 Financial Results

    Alex Rosenberg at GlobeNewswire2 mths ago

    NEW YORK and HERZLIYA-PITUACH, Israel, May 21, 2014 (GLOBE NEWSWIRE) -- Immune Pharmaceuticals Inc. (OTCQX:IMNP) and (IMNP.ST) ("Immune" or "the Company") announced today its financial results for the three month period ended March 31, 2014.

    "Immune has significantly strengthened its balance sheet and management team in the first quarter of 2014," said Dr. Daniel Teper, Chief Executive Officer of Immune Pharmaceuticals. "This provides us with enough cash to advance Bertilimumab, our first-in-class monoclonal antibody into our planned Phase 2 clinical trials in moderate-to-severe ulcerative colitis and bullous pemphigoid, an orphan auto-immune dermatological disease. Additionally, Immune is advancing Phase 3 planning and partnering of AmiKet, a topical Neuropathic Pain drug with Orphan Drug Designation for Post Herpetic Neuralgia (PHN). We believe that partnering of AmiKet will provide us with additional cash to fund further development of Bertilimumab."

    Operating Results for the Quarter Ended March 31, 2014:

    About Immune Pharmaceuticals Inc.

    Read More